/PRNewswire/ Mycovia Pharmaceuticals, Inc. ("Mycovia"), an emerging biopharmaceutical company, today announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Vaginal dysbiosis is a condition that can easily occur in a woman's life and can cause discomfort: now a clinically validated supplement can counteract it.
The global Vulvovaginal Candidiasis Treatment Market is currently valued at US$ 1035 Million in 2023 and is anticipated to expand at a CAGR of 4.5%. Owing to the technological advances in healthcare sector the market is likely to propel to US$1607 Million by 2033.VVC prevalence has increased due to growing diabetes.
The global Vulvovaginal Candidiasis Treatment Market is currently valued at US$ 1035 Million in 2023 and is anticipated to expand at a CAGR of 4.5%. Owing to the technological advances in healthcare sector the market is likely to propel to US$1607 Million by 2033.VVC prevalence has increased due to growing diabetes.